~~<i id='CA3577E091'><strike id='CA3577E091'><tt id='CA3577E091'><pre id='CA3577E091'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：explore 2025-09-27 12:47:28 - browse：147

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Oak trusses raised to roof of fire

entertainment

focus

hotspot

leisure time

focus

AdobeBigbusinessespoisedtoprofitfromtheadvanceofartificialintelligenceinhealthcarearepushingbackagai

WSS

Why 40% Americans with Parkinson’s don’t see a neurologist

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Biden tests positive for Covid

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Study: Pain burden is higher in Black NFL players than white ones

Elizabeth Holmes on track for early release from her 11

focus

Wikipedia

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

As digital health tech proliferates, a new institute aims to cut through hype

Medicare proposal to cover medical devices draws a mixed reaction

It's time to get medical device identifiers over the finish line

Hollywood unions extend contract negotiations for actors

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Walensky prepares to leave CDC — and Congress — behind

Elizabeth Holmes on track for early release from her 11

Hollywood unions extend contract negotiations for actors

Beach reads and more: STAT's 2023 summer book list

entertainment

Petition to FDA: Get the lead out of consumer hair dyes

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

FDA approves RSV monoclonal antibody for infants, toddlers

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Sanofi seeks simpler, safer CRISPR sickle cell cure

Biden launches a new push to limit health care costs

focus

hotspot

leisure time

focus